What this article helps you consider
- Define the structure of the formulation
- Characterise properties that may affect performance
- Distinguish release from skin permeation
Define the structure of the formulation
An emulgel combines an emulsion with a gelled structure, but the name alone does not describe its arrangement. Identify the continuous phase, dispersed phase, state of the active ingredient and relevant polymers or surfactants. Distinguish a dissolved active from suspended crystals or material associated with a carrier.
The location and physical state of the active can influence its availability for release. A total assay usually combines these populations and cannot show how the ingredient is distributed. Examine the structure that the user applies, including any change after dispensing or spreading.
Characterise properties that may affect performance
Relevant measurements may include pH, globule or particle size, microscopy, active-state characterisation and rheological behaviour. A single viscosity value at one speed gives limited information about a shear-dependent material. Flow curves, yield behaviour and recovery after shear can provide additional insight when measured with suitable methods.
FDA’s final March 2026 Q3 characterisation guidance addresses topical drug products submitted in ANDAs. In this context, Q3 means physicochemical and structural characterisation; it should not be confused with the unrelated ICH Q3 impurity guidelines. Its regulatory scope also differs from that of a cosmetic or nutraceutical topical product. R54
Distinguish release from skin permeation
In-vitro release testing, or IVRT, evaluates release from the formulation through a suitable membrane under defined conditions. In-vitro permeation testing, or IVPT, evaluates transport through skin under a different experimental design. They answer related but distinct questions and require different controls.
The illustration compares the two test systems. A membrane appropriate for release testing should not be treated as a model that proves skin penetration. Conversely, an IVPT result depends on skin integrity, donor variability, receptor conditions and dose application, making it unsuitable for interpretation as a simple formulation assay. FDA’s dedicated IVRT and IVPT documents were listed as drafts when checked. R55R56
A membrane release study and a skin study differ
Release through a suitable membrane assesses a formulation question under defined conditions.
Conceptual explanation. No product result, acceptance criterion or universal regulatory sequence is established by this illustration.
Develop methods that discriminate meaningfully
Select receptor conditions that maintain suitable analyte stability and measurement capability. Evaluate membrane interactions, sampling, recovery and the relevant sink conditions. A receptor medium that gives a large signal is not automatically suitable if it alters the test barrier or masks formulation differences.
A hypothetical reformulation may have the same assay and similar viscosity but a different release profile. Investigate active distribution, globule size, solvent activity and polymer interactions before deciding that the methods disagree. The tests may be describing different aspects of the same structural change.
Assess processing and storage effects
Mixing order, temperature, homogenisation, cooling and pH adjustment can influence the final structure. Reproducing an ingredient list does not necessarily reproduce an emulgel. Document the process variables that development evidence connects to important attributes.
During storage, examine phase separation, crystallisation, pH and rheology alongside chemical quality. Assess product removed from the actual container where dispensing could affect the structure. Heating and cooling tests can reveal vulnerabilities, but they do not replace a representative shelf-life programme.
Keep performance claims within the evidence
Smaller droplets or a vesicular structure do not by themselves establish deeper delivery, greater pain relief or reduced dose. Those claims require evidence suited to the mechanism and intended outcome. A successful in-vitro comparison may support development or a defined regulatory pathway without becoming a universal clinical-equivalence claim.
Stabicon can connect topical formulation work with analytical and performance characterisation, including identifying specialised study needs and partner responsibilities. This helps teams select a product using several relevant quality attributes rather than one convenient number.
References & further reading
Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.
- R54FDA Physicochemical and Structural Q3 Characterization of Topical Drug Products
Final guidance, March 2026. Topical drug products submitted in ANDAs.
- R55FDA In Vitro Release Test Studies for Topical Drug Products
Draft guidance, October 2022, as listed when checked. Pharmaceutical ANDA context.
- R56FDA In Vitro Permeation Test Studies for Topical Drug Products
Draft guidance, October 2022, as listed when checked. Pharmaceutical ANDA context.
- R05ICH Q14 Analytical Procedure Development
Final guideline adopted November 2023. Development and lifecycle approaches.
From insight to a defined programme
Bring your next technical question.
Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.
Discuss this topic with Stabicon






